(Q34274859)

English

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

S Miyamoto

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

N Miyake

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

L F Jarskog

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

W W Fleischhacker

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

J A Lieberman

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

15 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Molecular Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1206-1227

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Rethinking schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Schizophrenia: new pathological insights and therapies

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Emerging drugs for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Schizophrenia: moving beyond monoamine antagonists

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The pipeline and future of drug development in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

An update of fast-off dopamine D2 atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Dopamine partial agonists: a new class of antipsychotic

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Blonanserin: a review of its use in the management of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The glutamatergic dysfunction hypothesis for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Molecular targets for treating cognitive dysfunction in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Brain volume changes in first-episode schizophrenia: a 1-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The neuropathological effects of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Antipsychotic drug effects on brain morphology in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effect of second-generation antipsychotics on cognition: current issues and future challenges

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Another view of therapy for cognition in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Symptom domains of schizophrenia: the role of atypical antipsychotic agents

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Management of treatment resistance in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Suicide and schizophrenia: a systematic review of rates and risk factors

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Heterogeneity of violence in schizophrenia and implications for long-term treatment

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Substance abuse and schizophrenia: pharmacotherapeutic intervention

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Adverse effects of atypical antipsychotics : differential risk and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Antipsychotic drug use and mortality in older adults with dementia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Atypical antipsychotic drugs and the risk of sudden cardiac death

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Dopamine agonists in schizophrenia: a review

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Drugs in development for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Blockade of dopamine D₃ but not D₂ receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Serotonergic approaches in the development of novel antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Serotonergic basis of antipsychotic drug effects in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Therapeutic Potential of 5-HT2CReceptor Ligands

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Involvement of GABA systems in acetylcholine release induced by 5-HT3 receptor blockade in slices from rat entorhinal cortex

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

5-HT3 receptors

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Improved p50 auditory gating with ondansetron in medicated schizophrenia patients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The effect of Ondansetron on memory in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A review of central 5-HT receptors and their function

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Novel targets for drugs in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

5-HT6 receptor antagonists as potential therapeutics for cognitive impairment

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

5-HT system and cognition

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Free D-aspartate and D-serine in the mammalian brain and periphery

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

D-alanine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Glycine transporters: essential regulators of synaptic transmission

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Current and novel approaches to the drug treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Metabotropic glutamate receptors as therapeutic targets for cognitive disorders

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activiti

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Challenges for and current status of research into positive modulators of AMPA receptors.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Glutathione and signal transduction in the mammalian CNS.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Guanfacine treatment of cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Prefrontal neurons and the genetics of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Tolcapone improves cognition and cortical information processing in normal human subjects

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Neuroscience. Deconstructing schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Quality of life as a predictor for change in disability in MS.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Selective alpha7 nicotinic acetylcholine receptor ligands

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Initial phase 2 trial of a nicotinic agonist in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Neuronal nicotinic receptors: a perspective on two decades of drug discovery research

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Antipsychotics in the early stage of development

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Muscarinic receptors as a target for drugs treating schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Galantamine for the treatment of cognitive impairments in people with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The effects of galantamine on psychopathology in chronic stable schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Recent advances in histamine H3 receptor antagonists/inverse agonists.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The histamine H3 receptor: an attractive target for the treatment of cognitive disorders

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Cortical inhibitory neurons and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Prospects for minocycline neuroprotection

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Opinion: NK3 receptor antagonists: the next generation of antipsychotics?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Variation in symptom severity over the menstrual cycle of schizophrenics

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Estrogen in severe mental illness: a potential new treatment approach

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Estrogen - a potential treatment for schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS).

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Omega-3 fatty acids in the treatment of psychiatric disorders

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Omega-3 fatty acids: potential role in the management of early Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Oxytocin may mediate the benefits of positive social interaction and emotions

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Neuroendocrine perspectives on social attachment and love

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Oxytocin increases trust in humans

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Oxytocin improves "mind-reading" in humans

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Patented PDE10A inhibitors: novel compounds since 2007.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Immunohistochemical localization of PDE10A in the rat brain

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Inhibition of fear potentiated startle in rats following peripheral administration of secretin

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Partial reversal of phencyclidine-induced impairment of prepulse inhibition by secretin

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Secretin for refractory schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Secretin effects on cerebellar-dependent motor learning in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Multifunctional drugs: a novel concept for psychopharmacology

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

The evolution of drug development in schizophrenia: past issues and future opportunities

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Intervention in individuals at ultra-high risk for psychosis: a review and future directions

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

21 January 2018

Pharmacological strategies for enhancing cognition in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Antipsychotic drug development.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Negative symptoms: diagnosis, treatment and prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

D(1) receptors in prefrontal cells and circuits

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging drugs for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Varenicline-induced manic episode in a patient with bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Exacerbation of schizophrenia by varenicline

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Oestrogen--a new treatment approach for schizophrenia?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuroactive Steroids are Altered in Schizophrenia and Bipolar Disorder: Relevance to Pathophysiology and Therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythropoietin: a candidate compound for neuroprotection in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MP.2012.47

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34274859&oldid=2196450275"